Recombinant Capital Presents
ALLICENSE 2005
BALANCING R&D INVESTMENT & RISK
May 24 & 25, 2005
Westin St. Francis Hotel, San Francisco, CA
Program Agenda
All Speakers confirmed
Tuesday, May 24
8:00 – 8:15
Welcoming Remarks & Conference Overview: Balancing R&D Investment & Risk
· Mark G. Edwards, Managing Director, Recombinant Capital
8:15 – 9:00
Keynote Presentation – Medicine, Science & Merck
· P. Roy Vagelos, M.D., Chairman, Theravance, Inc., Chairman, Regeneron Pharmaceuticals, Inc. and Ex-Chairman and Chief Executive Officer, Merck & Co.
9:00 – 10:00
Session 1: The Changing Landscape of Big Pharma and Biotech – A Panel Discussion
· Session Chair: Kenneth Weg, Chairman, Clearview Projects and Former President, Worldwide Medicines Group, Bristol-Myers Squibb
· P. Roy Vagelos, M.D., Chairman, Theravance, Inc., Chairman, Regeneron Pharmaceuticals, Inc. and Ex-Chairman and Chief Executive Officer, Merck & Co.
· Stelios Papadopoulos, Ph.D., Vice Chairman, SG Cowen
10:00 – 10:30
Morning break hosted by:
10:30 – 12:30
Session 2: Is Licensing Now Leading the Way to the Commercialization of New Pharma Products?
· Session Chair: Tamar Howson, Senior Vice President, Corporate and Business Development, Bristol-Myers Squibb
·
· Frances Heller, Head, Strategic Alliances, Novartis
· Dr. Thomas Hofstaetter, Senior Vice President, Corporate Business Development, Wyeth
· Dr. Phil McGurk, Manager, Strategic Alliances, Pfizer
12:30 – 2:00
Luncheon hosted by:
2:00 – 3:00
Session 3: Anatomy of a New Pharma/Biotech Business Model
· Rick E. Winningham, Chief Executive Officer, Theravance
· Dr. Moncef Slaoui, Senior Vice President, Worldwide Business Development, GlaxoSmithKline
Afternoon Break 3:00 - 3:30
3:30 – 5:30
Session 4: Alliance Strategy & Management: A Roundtable Discussion
· Session Chair: Barbara Yanni, Vice President and Chief Licensing Officer, Merck & Co
· Joseph McCracken, Vice President, Business & Commercial Development, Genentech
· Dr. Jit Patel, Director, Global Discovery Alliances, AstraZeneca
· Dr. Thomas A. Picone, Vice President, Strategic Alliances, Schering-Plough
· Dr. Robert J. Wills, Vice President, Alliance Management, Johnson & Johnson
· Peter Wirth, Executive Vice President, Genzyme
ALLICENSE 2005 Breakthrough Alliance Awards Dinner
Westin St. Francis Hotel
Awards dinner reception sponsored by:
6:00 - 7:00 Cocktail Reception, The Italian Room Foyer
7:00 - 9:30 Dinner and Awards Ceremony, The Colonial Room
(All registered attendees are invited to attend the Reception and Awards Dinner)
.............................................................................
Wednesday, May 25
8:00 – 8:30
The ZymoGenetics – Serono Alliances: Focus and Flexibility
· Fredrik Henell, M.D., Ph.D., Senior Vice President, Business Development, ZymoGenetics
8:30 – 9:00
What is the Right Balance Between Too Big and Too Small? A Midcap Global Biopharma View
· Roch Doliveux, Chief Executive Officer, UCB Pharma
9:00 – 9:30
How to Fairly Split the Pie When You Can't Predict Its Size
· Thomas M. Finn, Vice President, Worldwide Strategic Planning - Pharmaceuticals, P&G Pharmaceuticals
9:30 – 10:00
Partnering Your Way to the Promised Land - Partnering with Pharma to Build It with
Wall Street
· Stephen R. Davis, Executive Vice President and Chief Operating Officer, Neurogen
Morning Break 10:00 – 10:30
10:30 – 12:30
Session 5: Balancing Focus & Openmindedness When Looking for Products & Partnerships
· Session Chair: Dr. Ronald A. Pepin, Senior Vice President, Business Development, Medarex
· Ed Broughton, Senior Vice President of Business Development and New Products, Eisai Inc.
· Nigel Sheail, Vice President, Global Head Licensing, Roche
· Joe Zakrzewski, Chief Operating Officer, Reliant Pharmaceuticals
Luncheon 12:30 – 2:00
2:00 – 3:30
Session 6: What are the Implications of Vioxx, Celebrex, Iressa and Tysabri for Licensing?
· Session Chair: Mark G. Edwards, Managing Director, Recombinant Capital
· Scott Foraker, Vice President Licensing, Amgen
· Barbara Kosacz, Head, Life Sciences Practice, Cooley Godward
· Mark C. Wiggins, Executive Vice President, Business Development, Biogen Idec
Afternoon Break 3:30 – 4:00
4:00 – 5:30
Session 7: Biotech Business Models - Strategies for a Challenging World
· Session Chair: Chris Ehrlich, Partner, InterWest Partners
· Jay Hagan, Managing Director, Amgen Ventures
· Robert Myers, Executive Vice President & Chief Business Officer, Jazz Pharmaceuticals
· William Greene M.D., General Partner, MPM Capital
Cocktail Reception 5:30 – 6:30
|